Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
09. Dezember 2024 16:05 ET
|
Myriad Genetics, Inc.
Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
03. Juni 2024 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official...
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
22. August 2023 09:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Onsite Women’s Health, a leading national provider of...
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
24. Juli 2023 08:00 ET
|
Myriad Genetics, Inc.
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers This comprehensive model is expected to identify more patients that could benefit...
Atossa Genetics Inc. Announces Pricing of a Public Offering of Common Stock and Warrants
24. Januar 2014 08:30 ET
|
Atossa Genetics Inc.
SEATTLE, WA--(Marketwired - Jan 24, 2014) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has priced a public offering of approximately 5.8 million units at a price to the public of...
Atossa Genetics Inc. Announces Proposed Public Offering of Common Stock and Warrants
23. Januar 2014 16:15 ET
|
Atossa Genetics Inc.
SEATTLE, WA--(Marketwired - Jan 23, 2014) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it intends to offer units consisting of shares of common stock and warrants in a public...
CONTEMPORARY OBSTETRICS AND GYNECOLOGY OF DAYTON ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
30. September 2013 10:34 ET
|
Genetic Technologies Group
DAYTON, Ohio, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Contemporary Obstetrics & Gynecology, part of the Providence Medical Group, today announced the availability of the BREVAGen™ predictive risk...
Atossa Genetics to Exhibit Its ForeCYTE Breast Health Test at the Breast Cancer Symposium 2013
06. September 2013 08:30 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Sep 6, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, will display its ForeCYTE Breast Health Test at the 7th annual Breast Cancer...
Atossa Genetics to Announce Second Quarter 2013 Results on Wednesday, August 14, 2013
06. August 2013 16:01 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Aug 6, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, today announced that it will issue financial results and corporate highlights for...
Atossa Genetics Added to Russell Microcap Index
15. Juli 2013 08:30 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Jul 15, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that the Company has been added to the Russell Microcap®...